1 The aim of this study was to identify the presence of matrix metalloproteinase-9 (MMP-9) in human platelets and systematically examine its inhibitory mechanisms of platelet activation. 2 In this study, we report on an efficient method for the quantitative analysis of pro-MMP-9 in human platelets using capillary zone electrophoresis (CZE). To elucidate subcellular localization of MMP-9 in human platelets, we investigated intraplatelet MMP-9 by immunogold labeling and visualized it using electron microscopy. In an in vivo thrombotic study, platelet thrombus formation was induced by irradiation of mesenteric venules with filtered light in mice pretreated with fluorescein sodium. 3 MMP-9-gold labeling was observed on the plasma membrane, a-granules, open canalicular system, and within the cytoplasma both in resting and activated platelets. Furthermore, activated MMP-9 concentration-dependently (15-90 ng ml À1 ) inhibited platelet aggregation stimulated by agonists. Activated MMP-9 (21 and 90 ng ml
Introduction
Matrix metalloproteinases (MMPs) are a family of Zn 2 þ -and Ca 2 þ -dependent enzymes, which are important in the resorption of extracellular matrices (ECMs) in both normal physiological processes and pathological states (Dollery et al., 1995) . These enzymes are responsible for the degradation of ECMs such as collagen, laminin, and proteoglycans (BirkedalHansen, 1995) . Therefore, MMPs have been implicated in the tissue remodeling, which accompanies inflammation, bone resorption, wound healing, thrombosis, atherosclerosis, and the invasion of tumors (Ray & Stetler-Stevenson, 1994) . Most MMPs are synthesized and secreted as inactive proenzymes (Lijnen, 2001) . MMPs expression appears to be strictly regulated by tissue inhibitors of metalloproteinases (TIMPs) (Ray & Stetler-Stevenson, 1994; Birkedal-Hansen, 1995) . Under some pathological conditions such as tumor cell metastasis, inflammation, thrombosis, and atherosclerosis, MMPs expression may be significantly increased over that of the TIMPs. MMP-9, also known as gelatinase B, has a broad range of substrate specificity for different native collagens (types IV, V, VII, and X) as well as denatured collagens (gelatin) and elastin (Ray & Stetler-Stevenson, 1994; Birkedal-Hansen, 1995) . MMP-9 is secreted as a 92-kDa proenzyme and can be activated to be an 86-kDa active form (Birkedal-Hansen, 1995) . Vascular smooth muscle and endothelial cells are known to synthesize and release MMPs including MMP-9 (Ray & Stetler-Stevenson, 1994; Sawicki et al., 1997) , suggesting that this protein may be involved in the process of hemostasis and/or thrombosis. Intravascular thrombosis is one of the generators of a wide variety of cardiovascular diseases. Initiation of intraluminal thrombosis is believed to involve platelet adherence and aggregation. Thus, platelet aggregation may play a crucial role in atherothrombotic processes. Fernandez-Patron et al. (1999) demonstrated that human platelets release MMP-9, and that it significantly inhibited platelet aggregation stimulated by thrombin. However, no data are available concerning the effect of MMP-9 on platelet activation. The detailed inhibitory mechanisms of MMP-9 underlying the signaling pathways in platelets still remain obscure. We therefore systematically examined the influence of MMP-9 on human platelets, and utilized the findings to characterize the mechanisms involved in this influence. Furthermore, the release of MMP-9 from human platelets has been demonstrated (Fernandez-Patron et al., 1999) . However, MMP-9 subcellular localization within the platelet is still unknown. Therefore, we performed immunogold labeling of MMP-9 on London Resin (LR) White-sections of resting and collagen-activated platelets. In addition, we previously reported that platelet thrombi were induced by irradiation with filtered light in the microvasculature of mice pretreated with fluorescein sodium (Sheu et al., 1994) . Therefore, we used this model to further evaluate the inhibitory effect of platelet plug formation by MMP-9 in vivo. Moreover, the amount of platelet-derived pro-MMP-9 was also determined by capillary zone electrophoresis (CZE) in this study.
Methods

Materials
Pro-MMP-9 was purchased from Calbiochem (San Diego, CA, U.S.A.). Collagen (type I, bovine achilles tendon), U46619, luciferin-luciferase, fluorescein sodium, Dowex-1 (100-200 mesh; X 8 , chloride form), myoinositol, prostaglandin E 1 (PGE 1 ), arachidonic acid, phorbol-12, 13-dibutyrate (PDBu), apyrase, osmium tetroxide, p-aminophenylmercuric acetate (APMA), gold-conjugated anti-mouse IgG, phenylmethylsulfonyl fluoride (PMSF), bovine serum albumin (BSA), and thrombin were purchased from Sigma Chem. (St Louis, MO, U.S.A.). Fura 2-AM was purchased from Molecular Probe (Eugene, OR, U.S.A.). LR White resin was purchased from London Resin Co. (Reading, U.K.). Anti-MMP-9 antibody was obtained from Oncogene (MA, U.S.A.). Myo-2-[ 3 H]inositol was purchased from Amersham (Buckinghamshire, HP, U.K.). Thromboxane B 2 (TxB 2 ), cyclic AMP, and cyclic GMP EIA kits were purchased from Cayman (Ann Arbor, MI, U.S.A.).
Preparation of human platelet suspensions
Human platelet suspensions were prepared as previously described (Sheu et al., 1999c) . In this study, human volunteers gave informed consent. In brief, blood was collected from healthy human volunteers who had taken no medicine during the preceding 2 weeks, and was mixed with acid/citrate/glucose (9 : 1, vol vol À1 ). After centrifugation at 120 g for 10 min at room temperature, the supernatant (platelet-rich plasma; PRP) was supplemented with PGE 1 (0.5 mM) and heparin (6.4 IU ml À1 ), then incubated for 10 min at 371C and centrifuged at 500 g for 10 min. The washed platelets were finally suspended in Tyrode's solution containing BSA (3.5 mg ml À1 ) and adjusted to about 4.5 Â 10 8 platelets ml
À1
. The final concentration of Ca 2 þ in Tyrode's solution was 1 mM.
Analysis of pro-MMP-9 in human platelets by capillary zone electrophoresis
Human platelets were homogenized by ultrasound sonication for 30 s at 41C in lysis buffer (1% SDS, 0.1%. Triton X-100, and 10 mM Tris-HCl, pH 7.4) containing protease inhibitors (PMSF, aprotinin, and leupeptin) and centrifuged at 30,000 g for 60 min at 41C. Supernatant was collected and stored at À851C. CZE was performed on a P/ACE System Model 2100 (Beckman, Fullerton, CA, U.S.A.) without coatings. Pro-MMP-9 was monitored with a fixed-wavelength detector at 214 nm. Beckman System Gold software was used for data processing. Separations were performed at 251C and 10 kV for 20 min. The authentic pro-MMP-9 (0.1 mg ml
) and supernatants were dissolved in a Tris-HCl solution (50 mM, pH 7.0) and subjected to CZE analysis. All samples were injected to P/ACE by positive pressure (0.5 psi for 10 s). The running buffer used was a boric acid-based electrolyte buffer solution (150 mM, pH 7.0). All separations were repeated at least four times to ensure reproducibility.
Postembedding immunolabeling for MMP-9
Resting and collagen (1 mg ml À1 )-activated human platelets were fixed with 2% paraformaldehyde and 2% glutaraldehyde in cacodylate buffer (0.1 M, pH 7.2) for 30 min. After rinsing with cacodylate buffer, platelets were further postfixed with 1% osmium tetroxide for 30 min. After dehydration in a graded series of ethanol, samples were embedded in LR White resin. Ultrathin sections were mounted on Formvar-coated nickel grids, and were blocked for 20 min with 1% BSA in cacodylate buffer. Sections were incubated for 1 h with mouse monoclonal anti-MMP-9 antibody (1 : 1000), which raised against pro-MMP-9 and/or activated MMP-9 or control mouse IgG (0.05 mg ml À1 ) with cacodylate buffer. After rinsing with cacodylate buffer, sections were incubated for 1 h with 10 nm of gold-conjugated anti-mouse IgG (1 : 100) with cacodylate buffer. Sections were treated with 2% uranyl acetate and lead citrate, and were examined with a Hitachi H-600 electron microscope.
Platelet aggregation
The turbidimetric method was applied to measure platelet aggregation (Born & Cross, 1963) , using a Lumi-Aggregometer (Payton, Canada). Pro-MMP-9 was activated by AMPA (10 mM) as described by Marcy et al. (1991) . Platelet suspensions (4.5 Â 10 8 platelets ml
À1
, 0.4 ml) were prewarmed to 371C for 2 min, activated MMP-9 (15-90 ng ml
) and a solvent control (10 mM AMPA) were added 3 min before the addition of agonists. The reaction was allowed to proceed for at least 6 min, and the extent of aggregation was expressed in light-transmission units. While measuring ATP release, 20 ml of a luciferin/luciferase mixture was added 1 min before the addition of agonists, and ATP release was compared with that of the control.
Labeling of membrane phospholipids and measurement of the production of [ 3 H]inositol phosphates
The method was carried out as previously described (Sheu et al., 1999c) . Briefly, citrated human PRP was centrifuged, and the pellets were suspended in Tyrode's solution containing [ ). Platelets were incubated for 2 h followed by centrifugation, and were finally resuspended in Ca 2 þ -free Tyrode's solution (5 Â 10 8 ml
). Activated MMP-9 (21 and 90 ng ml À1 ) was preincubated with 1 ml of loaded platelets for 3 min, and collagen (1 mg ml
) was then added to trigger aggregation. The reaction was stopped, and samples were centrifuged for 4 min. The inositol phosphates of the supernatants were separated in a Dowex-1 anion exchange column. Only [ 3 H]inositol monophosphate (IP) was measured as an index of total inositol phosphate formation.
Measurement of platelet [Ca 2 þ ]i mobilization by fura 2-AM fluorescence
Citrated whole blood was centrifuged at 120 g for 10 min. The supernatant was incubated with Fura 2-AM (5 mM) for 1 h. Human platelets were then prepared as described above. Finally, the external Ca 2 þ concentration of the platelet suspensions was adjusted to 1 mM. The [Ca 2 þ ]i rise was measured using a fluorescence spectrophotometer (CAF 110, Jasco, Tokyo, Japan) with excitation wavelengths of 340 and 380 nm, and an emission wavelength of 500 nm. The [Ca 2 þ ]i was calculated from the fluorescence measured using 224 nM as the Ca 2 þ -Fura 2 dissociation constant (Grynkiewicz et al., 1985) .
Measurement of thromboxane B 2 formation
Platelet suspensions (4.5 Â 10 8 ml
À1
) were preincubated for 3 min in the presence or absence of activated MMP-9 (21 and 90 ng ml
) before the addition of collagen (1 mg ml À1 ). At 6 min after the addition of agonists, 2 mM EDTA and 50 mM indomethacin were added to the reaction suspensions. The vials were then centrifuged for 3 min at 15,000 g. The TxB 2 levels of the supernatants were measured using an EIA kit according to the instructions of the manufacturer.
Estimation of nitrate, cyclic AMP, and cyclic GMP formations NO was assayed in platelet suspensions as previously described (Sheu et al., 1999a) . In brief, platelet suspensions (1 Â 10 9 ml À1 ) were preincubated with collagen (1 mg ml
) or activated MMP-9 (21 and 90 ng ml À1 ) for 6 min, respectively, followed by centrifugation. The amount of nitrate in the platelet suspensions (10 ml) was measured by adding a reducing agent (0.8% VCl 3 in 1 M HCl) to the purge vessel to convert nitrate to NO, which was stripped from the platelet suspensions by a helium purge gas. The NO was then drawn into a Sievers Nitric Oxide Analyzer (Sievers 280 NOA, Sievers Inc., Boulder, CO, U.S.A.). Nitrate concentrations were calculated by comparison with standard solutions of sodium nitrate.
The method of Karniguian et al. (1982) for measurement of cyclic AMP and cyclic GMP was followed. In brief, platelet suspensions were incubated with nitroglycerin (10 mM) and activated MMP-9 (21 and 90 ng ml À1 ) for 6 min. The incubation was stopped, and the solution was immediately boiled for 5 min. In total, 50 ml of supernatant was used to determine the cyclic AMP and cyclic GMP contents with EIA kits following acetylation of the samples as described by the manufacturer.
Measurement of protein kinase C activity
Washed platelets (2 Â 10 9 ml
À1
) were incubated for 60 min with phosphorus-32 (0.5 mCi ml
). The [ 32 P]labeled platelets were incubated with activated MMP-9 (21 and 90 ng ml À1 ) for 3 min, then PDBu (60 nM) was added for 1 min to trigger protein kinase C activation. Activation was terminated by the addition of Laemmli sample buffer, and analyzed by electrophoresis (12.5%; wt vol À1 ) as described previously (Grabarek et al., 1992) . The gels were dried, and the relative intensities of the radioactive bands were analyzed using a Bio-imaging analyzer system (FAL 2000, Fuji, Tokyo, Japan), and expressed as PSL mm À2 (PSL, photostimulated luminescence).
Fluorescein sodium-induced platelet thrombi in mesenteric microvessels of mice
As we previously described (Sheu et al., 1994) , mice were anesthetized with sodium pentobarbital (50 mg kg À1 , i.p.). After a tracheotomy was performed, an external jugular vein was cannulated with polyethylene tubing (PE-10) for administration of the dye and drug (by an i.v. bolus). A segment of the small intestine with its mesentery attached was loosely exteriorized through a midline incision in the abdominal wall and was placed onto a transparent culture dish for microscopic observation. Venules with diameters of 30-40 mm were selected for irradiation to produce a microthrombus. Filtering the light eliminated wavelengths below 520 nm, and this light was used to irradiate a microvessel (the area of irradiation was about 100 mm in diameter on the focal plane) through an objective lens ( Â 20). The dose of fluorescein sodium used was 15 mg kg
. Various doses of activated MMP-9 (0.5 and 1.0 mg g À1 ), aspirin (150 and 250 mg g À1 ) or solvent control (10 mM AMPA) were administered 1 min after fluorescein sodium addition. The time lapse for inducing thrombus formation leading to cessation of blood flow was measured.
Statistical analysis
The experimental results are expressed as the means7s.e.m. and are accompanied by the number of observations. Data were assessed using analysis of variance (ANOVA). If this analysis indicated significant differences among the group means, then each group was compared using the NewmanKeuls method. A P-valueo0.05 was considered statistically significant.
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Results
Quantification of pro-MMP-9 in washed human platelets
Accurate quantification of pro-MMP-9 was extremely important to this study. This study is the first to report a fast, simple, efficient method for analysis of pro-MMP-9 using CZE. This technique has a higher peak capacity and resolution, and improved reproducibility compared with HPLC. The relative migration time of the pro-MMP-9 peak was about 3.3 min (indicated by an arrow) (Figure 1a) . Identification of the peak, corresponding to the pro-MMP-9 compound, was based on the use of authentic pro-MMP-9 and anti-MMP-9 antibody. For example, authentic pro-MMP-9 compound and anti-MMP-9 antibody were mixed with sample, and then applied to CZE under the same conditions, we found that the peak eluted at 3.3 min were superimposed and disappeared, respectively, indicating that this peak corresponded to the pro-MMP-9 compound (data not shown). Figure 1b shows the regression line of cell number vs total amount of pro-MMP-9 in human platelets. A correlation coefficient (r 2 ) of about 0.94 was obtained form this line. This result reveals that no obvious variation in the ratio of cells associated with the amount of pro-MMP-9 was observed. The amount of pro-MMP-9 in human platelets was calculated to be about 8.870.7 ng 10 À6 cells (n ¼ 4).
Distribution of MMP-9 in resting and activated platelets
Immunogold labeling on LR White-sections of resting platelets revealed that the cytoplasma was the main storage compartment for MMP-9 (Figure 2b ). Some gold particles were labeled on the plasma membrane and a-granules, whereas there is only a little labeling on open canalicular system (OCS). To determine whether platelet activation might cause changes in MMP-9 labeling, we processed collagen-activated platelets in the same way, and they showed a marked increase in labeling of MMP-9 in the cytoplasma, on the plasma membrane, and on the OCS, but with only a little labeling on a-granules (Figure 2d ). On the other hand, no labeling reaction was visible on cytoplasma, OCS, or a-granules in control preparations incubated with normal nonimmune mouse IgG in resting and activated platelets, respectively (Figure 2a and c) .
Effect of activated MMP-9 on platelet aggregation in human platelets
Zymographic analysis confirmed that pro-MMP-9 (92-kDa) was activated by AMPA (10 mM) to form an 86-kDa activated MMP-9, as shown by gelatinolytic activities (data not shown).
In subsequent experiments, we used this activated MMP-9 to investigate antiplatelet activity. Activated MMP-9 (15-90 ng ml
À1
) concentration-dependently inhibited platelet aggregation stimulated by collagen (1 mg ml ). Furthermore, activated MMP-9 also inhibited the ATP-release reaction when stimulated by agonists (i.e. collagen) (Figure 3a) . IC 50 values of activated MMP-9 for platelet aggregation induced by collagen, thrombin, ADP, U46619, and arachidonic acid were estimated to be approximately 21, 54, 64, 49, and 5.4 ng ml À1 , respectively. Furthermore, platelets were preincubated with a higher concentration of activated MMP-9 (150 ng ml À1 ) or normal saline for 10 min, followed by two washes with Tyrode's solution, we found that there were no significant differences between the aggregation curves of either platelet preparations stimulated by collagen (1 mg ml À1 ), indicating that the effect of activated MMP-9 on inhibition of platelet aggregation occurs in a reversible manner (data not shown). In contrast to activated MMP-9, neither pro-MMP-9 (10 mg ml
) nor AMPA (10 mM) significantly inhibited collagen (1 mg ml À1 )-or thrombin (0.01 U ml À1 )-induced platelet aggregation (data not shown). In subsequent experiments, we used collagen as an agonist to explore the inhibitory mechanisms of activated MMP-9 in platelet aggregation. Figure 1 Various concentrations of human platelets were homogenized by ultrasound sonication in lysis buffer followed by centrifugation. The supernatants were applied into the capillary zone electrophoresis (CZE) system for the quantitative analysis of pro-MMP-9 as described in 'Methods'. (a) Profile of pro-MMP-9 using the CZE system performed. One peak of the pro-MMP-9 compound was eluted at about 3.3 min (arrow). (b) Linear regression line of the amount of pro-MMP-9 vs various concentrations of human platelets. The line is a representative example for four similar experiments.
Effect of activated MMP-9 on phosphoinositide breakdown in human platelets
Phosphoinositide breakdown occurs in platelets activated by many different agonists (Broekman et al., 1980) . In this study, we found that collagen (1 mg ml Figure 4 , the addition of collagen (1 mg ml À1 ) resulted in a rise of IP formation of about 2.1-fold compared to that in resting platelets ([26.070.3 vs 12.570 .5] Â 10 3 cpm). In the presence of activated MMP-9 (21 and 90 ng ml À1 ), the radioactivity of IP formation in collagen-stimulated human platelets markedly decreased. In addition, we also found that activated MMP-9 (90 ng ml À1 ) also significantly inhibited the IP formation in thrombin (0.5 U ml À1 )-stimulated human platelets (data not shown).
Effect of activated MMP-9 on [Ca 2 þ ]i mobilization
Free cytoplasmic Ca 2 þ concentrations in human platelets were measured by the Fura 2-AM loading method. As shown in Effect of activated MMP-9 on thromboxane B 2 , nitrate, cyclic AMP, and cyclic GMP formations in human platelets
As shown in Table 1 , resting platelets produced relatively little TxB 2 compared with collagen-activated platelets. Activated MMP-9 (21 and 90 ng ml À1 ) significantly inhibited TxB 2 formation in platelets stimulated by collagen (1 mg ml À1 ). Furthermore, NO was quantified using a sensitive and specific ozone redox-chemiluminescence detector. As shown in Table 1 , collagen (1 mg ml À1 ) caused about a 3.8-fold rise in nitrate formation, compared to that in resting platelets. In the presence of activated MMP-9 (21 and 90 ng ml À1 ), nitrate production significantly increased after incubation with washed platelets. In addition, the level of cyclic GMP in resting platelets was about 5.770.2 pmol ml À1 . The addition of nitroglycerin (10 mM) increased the cyclic GMP level to 12.671.6 pmol ml À1 (Table 1 ). The addition of activated MMP-9 (21 and 90 ng ml
À1
) resulted in significant increases in platelet cyclic GMP levels (Table 1) . On the other hand, activated MMP-9 (21 and 90 ng ml À1 ) did not significantly increase the cyclic AMP levels in human platelets (data not shown).
Effect of activated MMP-9 on phorbol-12, 13-dibutyratestimulated phosphorylation of the 47-kDa protein Stimulation of platelets with a number of different agonists, and PDBu in particular, induces activation of protein kinase 
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Activated MMP-9 inhibits platelet aggregation 197 C, which then phosphorylates proteins of Mr 40,000-47,000 in addition to other proteins (Siess & Lapetina, 1989) . In this study, phosphorylation experiments were performed to examine the role of activated MMP-9 in the activation of protein kinase C in human platelets. When PDBu (60 nM) was added to human platelets prelabeled with 32 PO 4 , a protein with an apparent Mr of 47,000 (P47) was predominately phosphorylated as compared with resting platelets (Figure 6 ). Activated MMP-9 (21 and 90 ng ml À1 ) markedly inhibited the phosphorylation of P47 stimulated by PDBu. In this study, the extent of radioactivity in P47 was expressed as a relative detection density (PSL mm
À2
; PSL, photostimulated luminescence) of the radioactive bands. Moreover, activated MMP-9 (21 and 90 ng ml À1 ) also significantly inhibited collagen (1 mg ml À1 )-induced phosphorylation of P47 in human platelets (data not shown).
Effect of activated MMP-9 on thrombus formation in microvessels of fluorescein sodium-pretreated mice When 15 mg kg À1 of fluorescein sodium was given, the occlusion time required was 4.770.5 min (Figure 7) . When activated MMP-9 was administered at 0.5 mg g À1 in mice pretreated with fluorescein sodium (15 mg kg À1 ), the occlusion time was not significantly prolonged (5.370.4 min). However with 1 mg g À1 of activated MMP-9, the occlusion time was markedly prolonged (7.470.7 min) (Figure 7) . On the other hand, aspirin also exhibited antithrombotic activity in this experiment. When 250 mg g À1 of aspirin was administered, the occlusion time was prolonged (Figure 7) . Activated MMP-9 was over about 1 Â 10 4 -fold more potent than aspirin at prolongation of occlusion time in microvessels on a molar basis. 
Discussion
The results obtained from this study demonstrate for the first time the presence of MMP-9 both in resting and activated human platelets by quantitative and qualitative assays. CZE analysis detected the presence of pro-MMP-9 in the homogenate of resting platelets. Using electron microscopy, the presence of MMP-9 (pro-MMP-9 and/or activated MMP-9) immunoreactivity was labeled in the cytoplasma, OCS, and a-granules both in resting and activated platelets. These results clearly indicate that pro-MMP-9/activated MMP-9 is present in human platelets. In addition, the principal objective of this study was to describe the detailed inhibitory mechanisms of activated MMP-9 in platelet activation. This inhibitory effect of activated MMP-9 was demonstrable with the use of various agonists: collagen, thrombin, ADP, U46619, and arachidonic acid. The inhibition was directly proportional to the pharmacological concentrations of activated MMP-9 used. Nakamura et al. (1998) suggested that human plasma MMP-9 concentrations ranged from 34.2716.6 to 52.4726.6 ng ml À1 . In this study, activated MMP-9 was employed at concentrations of about 15-90 ng ml
À1
, which inhibited platelet aggregation induced by agonists. This result indicates that the pharmacological concentrations of activated MMP-9 employed to inhibit platelet aggregation in vitro are reasonably close to those of physiological concentrations obtained for plasma In this study, platelet aggregation induced by these agonists (i.e. collagen) appeared to be affected in the presence of activated MMP-9. Therefore, this partly infers that activated MMP-9 may affect Ca 2 þ release from intracellular Ca 2 þ -storage sites (i.e. dense tubular systems or dense bodies), and this is in accord with the concept that intracellular Ca 2 þ release is responsible for platelet aggregation (Charo et al., 1976) . Moreover, this inhibitory effect of activated MMP-9 was dependent on the catalytic activity of this enzyme since the zymogen, pro-MMP-9, did not significantly inhibit platelet aggregation stimulated by agonists. These data also indicate that MMP-9 generated in an autocrine or paracrine way regulates platelet aggregation.
Although the action mechanisms of various platelet aggregation agonists, such as collagen, thrombin, ADP, U46619, and arachidonic acid, differ, activated MMP-9 significantly inhibited platelet aggregation stimulated by all of them. This implies that activated MMP-9 may block a common step shared by these inducers. These results also indicate that the site of action of activated MMP-9 is not at the receptor level of individual agonists. Stimulation of platelets by agonists (i.e., collagen) results in phospholipase C-catalyzed hydrolysis of the minor plasma membrane phospholipid, phosphatidylinositol 4,5-bisphosphate, with concomitant formation of inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (Kirk et al., 1981) . There is strong evidence that IP 3 induces the release of Ca 2 þ from intracellular stores (Berridge, 1983) . Diacylglycerol activates protein kinase C, inducing protein phosphorylation and a release reaction. In this study, phosphoinositide breakdown of collagen-activated platelets was inhibited by activated MMP-9, suggesting that inhibition of platelet aggregation by activated MMP-9 is related to inhibition of phospholipase C activation. Moreover, TxA 2 is an important mediator of the release reaction and aggregation of platelets (Hornby, 1982) . Collagen-induced TxB 2 formation, a stable metabolite of TxA 2 , was markedly inhibited by activated MMP-9. It has been demonstrated that phosphoinositide breakdown can induce TxA 2 formation via free arachidonic acid release by diglyceride lipase or by endogenous phospholipase A 2 from membrane phospholipids (McKean et al., 1981) . Thus, it seems likely that TxB 2 formation plays a role in mediating the inhibitory effect of activated MMP-9 on human platelets.
Furthermore, activated MMP-9 significantly inhibited PDBu-induced activation of protein kinase C. PDBu is known to intercalate with membrane phospholipids and form a complex with protein kinase C translocated to the membrane (Kraft & Anderson, 1983) . Moreover, increased cyclic GMP can negatively affect agonist-induced protein kinase C activation (Murohara et al., 1995) . Signaling by cyclic GMP somehow interferes with the agonist-stimulated phosphoinositide turnover that creates Ca 2 þ -mobilizing second messengers (McDonald & Murad, 1996) . Activated MMP-9 increases the level of cyclic GMP in human platelets; therefore, the inhibitory effect of activated MMP-9 in PDBu-induced activation of protein kinase C may be due, at least partly, to mediating the increase in cyclic GMP. In this study, we found that activated MMP-9 induced NO formation in human platelets. This result is in accord with the result of a cyclic GMP study, because most cellular actions of NO occur via stimulation of intracellular guanylate cyclase, leading to an increase in cyclic GMP (McDonald & Murad, 1996) . 2 1 F 5.870.8*** 9.570.9** 90 F 6.670.5*** 11.770.6*** Platelet suspensions were preincubated with activated MMP-9 (21 and 90 ng ml À1 ) for 3 min at 371C, and then collagen (1 mg ml
) was added to trigger thromboxane B 2 formation. Addition of nitroglycerin into the platelet suspensions served as positive control of cyclic GMP. Data are presented as the means7s.e.m. (n ¼ number). ** Po0.01 and ***Po0.001 as compared with the resting groups; ### Po0.001 as compared with the collagen group.
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Activated MMP-9 inhibits platelet aggregationPlatelet aggregation plays a pathophysiological role in a variety of thromboembolic disorders. Therefore, inhibition of platelet aggregation by drugs may represent an increased therapeutic possibility for such diseases. We have demonstrated that endothelial cell injury induces platelet aggregation and adhesion to the vessel wall in vivo (Sheu et al., 1999b) . In this study, activated MMP-9 significantly prolonged the occlusion times in mice mainly through its inhibition of platelet aggregation.
In conclusion, the most important findings of this study suggest that activated MMP-9 can markedly inhibit agonistinduced platelet aggregation. This inhibitory effect may possible involve the following two mechanisms. (1) Activated MMP-9 may inhibit the activation of phospholipase C, followed by inhibition of phosphoinositide breakdown and thromboxane A 2 formation, thereby leading to inhibition of the activation of protein kinase C and intracellular Ca 2 þ mobilization. (2) Moreover, activated MMP-9 increases NO/ cyclic GMP formation and subsequently inhibits phosphoinositide breakdown and protein kinase C activity, ultimately resulting in inhibition of both the phosphorylation of P47 and intracellular Ca 2 þ mobilization. The important findings for vascular thrombosis suggest that MMP-9 appears to represent a novel platelet-regulatory system based on its antiaggregatory effect. Therefore, it is possible that an imbalance in the generation and/or release of MMP-9 contributes to pathological vascular diseases associated with platelet aggregation such as stroke, atherosclerotic plaque rupture, myocardial infarction, and thrombosis. We therefore believe that our data represent a physiologically relevant function for MMP-9 as a negative feedback regulator during platelet activation. When MMP-9 accumulates in the microenvironment of a generating thrombus, the recruitment and activation of nearly platelets is then prevented. However, the physiological relevance of a direct antiaggregatory effect of MMP-9 still remains to be further studied. 
